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Associations between the 17q21 region and
allergic rhinitis in 5 birth cohorts
To the Editor:
The high heritability and comorbidity between allergic
rhinitis and asthma suggest common etiologies and genetic
susceptibility loci. Among the most robust signals for asthma is
the chromosomal locus 17q21.1 Studies that examined whether
this strong asthma locus is also associated with allergic rhinitis 2014 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).have yielded conflicting results. A recent large genome-wide
association study (GWAS)2 and a candidate gene study3
identified associations between genetic variants at the 17q21
locus and allergic rhinitis, in contrast to null findings in
previous GWASs on allergic rhinitis4,5 and self-reported allergy.6
Large, well-defined studies are needed to clarify these
inconsistencies.
We pooled data from 5 birth cohorts not included in the
aforementioned GWASs (Children, Allergy, Milieu, Stockholm,
Epidemiological Survey [BAMSE], Canadian Asthma Primary
Prevention Study [CAPPS], German Infant study on the influence
of Nutritional Intervention plus environmental and genetic
influences on allergy development [GINIplus]/Lifestyle-related
factors, Immune System and the development of Allergies in East
and West Germany plus the influence of traffic emissions and
genetics study [LISAplus], Prevention and Incidence of Asthma
and Mite Allergy [PIAMA], and Study of Asthma Genes and the
Environment [SAGE]; Ntotal 5 4624 children, 92.7% white) and
examined whether 7 single nucleotide polymorphisms (SNPs) at
the 17q21 locus are associated with allergic rhinitis from early
childhood to adolescence, and the effects of comorbidity with
asthma on the associations.
Allergic rhinitis was defined as concomitantly reported rhinitis
and positive sensitization to any aeroallergen (age range 4-16
years in pooled data). Seven SNPs, including top GWAS hits
for asthma (rs7216389 and rs2305480),1 were extracted from
genotyped (BAMSE) or imputed genome-wide (other cohorts)
data and coded as 0, 1, and 2 according to the number of effect
alleles. Cohort-specific study designs, outcome definitions, and
genotyping/imputation are provided in this article’s Methods
section and Table E1 in the Online Repository at www.
jacionline.org. The effect of each SNP on allergic rhinitis over
time was analyzed using generalized estimating equation models
(logit link and exchangeable correlation structure) adjusted for
age and cohort (pooled models only). Associations were
calculated per cohort and in the combined pooled data. Odds
ratios with corresponding 95% CIs are presented.
Allergic rhinitis was reported at least once by 969 of the 4624
children (Table I). The proportion of cases generally increased
with age (see Table E2 in this article’s Online Repository at
www.jacionline.org). Effect allele frequencies were very similar
across cohorts for all SNPs (see Table E3 in this article’s Online
Repository at www.jacionline.org). The correlation between 5
of the SNPs (rs2305480, rs7216389, rs4065275, rs8076131, and
rs12603332) was high (r2 > 0.7, D9 > 0.9) and more moderate
between these 5 SNPs and the other 2 (r2 < 0.3, D9 > 0.9;
rs17608925 and rs3744246).
Allergic rhinitis and 6 of the 7 studied SNPs were significantly
associated in the pooled data (Table I). Because the SNPs are in
high linkage disequilibrium, the associations are not independent.
Cohort-specific risk estimates were consistent across all cohorts
except the smallest cohort CAPPS (see Table E4 in this article’s
Online Repository at www.jacionline.org). Associations stratified
by sex were significant only among males, although the direction
of effects was similar in males and females (data not shown).
Sensitivity analyses were conducted to assess whether
associations with allergic rhinitis were modified by the
copresence of asthma. Associations between the 17q21 variants
and allergic rhinitis with concomitant asthma appeared more
pronounced (although not significantly) than when allergic
rhinitis or asthma was modeled independently (Table I). Risk
TABLE I. Pooled longitudinal associations between 7 SNPs at the 17q21 locus and health outcomes*
SNP Gene
Effect
allele EAF
Allergic rhinitisy
(case ever 5 969 of 4624)
Asthmaz
(case ever 5 571 of 4619)
Allergic rhinitis with
concomitant asthma§
(case ever 5 234 of 4019)
Allergic rhinitis without
concomitant asthma§
(case ever 5 816 of 4425)
N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI)
rs2305480 GSDMB A 0.45 4605 0.85 (0.77-0.94)jj 4600 0.83 (0.72-0.96)jj 4002 0.72 (0.59-0.88)jj 4407 0.89 (0.80-0.99)jj
rs7216389 GSDMB T 0.49 4604 1.15 (1.04-1.27)jj 4599 1.15 (1.01-1.32)jj 4001 1.35 (1.12-1.63)jj 4408 1.10 (0.99-1.22)
rs4065275 ORMDL3 G 0.50 4421 1.14 (1.03-1.26)jj 4417 1.13 (0.98-1.29) 3859 1.35 (1.11-1.64)jj 4266 1.09 (0.98-1.22)
rs8076131 ORMDL3 G 0.45 4417 0.86 (0.77-0.95)jj 4413 0.85 (0.73-0.98)jj 3856 0.73 (0.60-0.89)jj 4262 0.89 (0.80-1.00)jj
rs12603332 ORMDL3 C 0.50 4618 1.15 (1.04-1.27)jj 4426 1.13 (0.98-1.29) 4014 1.34 (1.11-1.61)jj 4420 1.10 (0.99-1.23)
rs17608925 ORMDL3 C 0.11 4414 0.88 (0.74-1.05) 4410 0.99 (0.79-1.25) 3853 0.94 (0.67-1.32) 4259 0.89 (0.74-1.07)
rs3744246 ORMDL3 T 0.20 4607 0.86 (0.75-0.97)jj 4602 0.89 (0.75-1.06) 4004 0.83 (0.65-1.06) 4411 0.89 (0.77-1.02)
Case ever, Whether a child ever had a positive report at any follow-up; EAF, effect allele frequency; GSDMB, gasdermin B; N, number of children included in the model; OR, odds
ratio; ORMDL3, ORM1-like protein 3.
*Models were adjusted for age and cohort.
Age-specific controls were defined as those without allergic rhinitis. P values of significant pooled associations ranged from .002 for rs2305480 to .017 for rs3744246. Bonferroni-
corrected P value corresponds to .05/7 5 .007. The associated SNPs are in linkage disequilibrium (r2 > 0.2, D9 > 0.9).
Age-specific controls were defined as those without asthma.
§Age-specific controls were defined as those without allergic rhinitis or asthma.
jjP < .05.
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FIG 1. Pooled longitudinal associations between the 17q21 SNPs and allergic rhinitis, stratified by early-life
(3-8 years) (A) and ever (B) asthma (black squares 5 yes; stars 5 no). Models were adjusted for age and
cohort and only included cohorts with data on early-life asthma (BAMSE, GINI/LISA, and PIAMA). Controls
were defined as children with no allergic rhinitis or asthma.
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appeared smaller but were also significant/borderline significant
for 5 SNPs in high linkage disequilibrium. Associations with
allergic rhinitis were similar after adjustment for asthma during
early life (3-8 years). However, stratified analyses indicated that
associations between the SNPs and allergic rhinitis were
significant only among those with a history of asthma (Fig 1).
In our study, risk estimates for the 17q21 locus with concom-
itant allergic rhinitis and asthma appeared largest, which isintuitive given that significant associations were observed for
asthma and allergic rhinitis modeled independently. These results
have been observed by others2 and may suggest that the 17q21
locus is involved in the development of multiple clinical
manifestations or a more severe type of disease, possibly via a
causal pathway involving asthma. An asthma-dependent
mechanism is supported by the stratified analyses in which
associations between the SNPs and allergic rhinitis were most
pronounced for those with a history of asthma. Furthermore, the
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for allergic rhinitis.2 Nevertheless, because weaker borderline
significant longitudinal associations for allergic rhinitis without
concomitant asthmawere also observed, we are unable to exclude
the possibility that any effect of 17q21 variation on allergic
rhinitis may also be mediated through an asthma-independent
pathway, as has been suggested by others.3 However, the null
associations with allergic rhinitis for those without any history
of asthma observed in this study do not support this hypothesis
(Fig 1).
Allele-specific differences in gene expression at 17q21 are
being investigated.7,8 However, how these genes (and other
genetic, epigenetic, and gene-environment influences) may affect
asthma or allergic rhinitis development remains under study.
A functional role for ORM1-like protein 3 in regulating
eosinophil trafficking, recruitment, and degranulation via the
regulation of integrins and CD48 was recently identified.9
Because eosinophils are involved in immune and inflammatory
responses to allergens, this may represent a possible mechanism
by which 17q21 variation affects allergic asthma and allergic
rhinitis.
Our study results are based on a substantially larger sample size
and longer follow-up than any previous candidate-gene study for
allergic rhinitis studying this region. It is noteworthy that the
cohort-specific analyses, although consistent in trend, did not
independently reach statistical significance in almost all cases.
This highlights the need to carefully pool or meta-analyze
homogenous data to achieve sufficient statistical power. It
nevertheless remains possible that our study may have had less
power to detect associations that were found to be without or with
borderline significance. The SNPs studied were limited to those
available for the largest subset of the cohorts, which included top
hits from previous asthma GWASs.1 It is reassuring that
we observed significant associations for 6 of the 7 SNPs
(which were in high linkage disequilibrium) and that associations
were consistent across cohorts despite slightly different
outcome definitions (doctor diagnoses [CAPPS, GINI/LISA,
and SAGE], rhinitis symptom reports [PIAMA], or both
[BAMSE]). This consistency also argues against the interpreta-
tion that the results are due to chance. Furthermore, associations
between allergic rhinitis and the 17q21 locus would have
remained significant after a very conservative Bonferroni correc-
tion (Table I).
In summary, genetic variants at the 17q21 locus were
significantly associated with allergic rhinitis, primarily with
concomitant asthma, in a pooled longitudinal analysis of 5 birth
cohorts. These results support the hypothesis of a shared genetic
susceptibility between asthma and allergic rhinitis.
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Increased noneosinophilic nasal polyps in
chronic rhinosinusitis in US second-generation
Asianssuggestgeneticregulationofeosinophilia
To the Editor:
Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) is
an inflammatory disease with a high impact on quality of life and
is characterized by the presence of polyps in an individual with
diagnosis of CRS. Although most of the nasal polyps (NPs) in
patients with CRSwNP seen in Western countries are eosino-
philic,1,2 noneosinophilic NPs comprise a significant percentage
of CRSwNP seen in East Asian countries including China, Korea,
Japan, and Malaysia.3-8 Studies comparing polyps in Chinese and
Belgian patients have shown significantly lower eosinophil
numbers3,9 and lower eosinophil cationic protein (ECP) levels9
in NPs in Chinese patients.
In the last decade, there has been a trend toward increasing
eosinophilic nasal polyposis in Asian populations.5,10 A Korean
study has shown that eosinophilic NPs have increased from24% of the total NPs resected in 1993-1994 to 50.9% in
2010-2012.5 However, recent studies still show that about half
of the CRSwNP cases in East Asian countries have a noneosino-
philic pathology.4-8 This raises the possibility that this type of NPs
are influenced by different pathogenesis elements that are more
common in that area and/or that genetic factors play a role in
the level of eosinophilia in NPs in Asian populations.
In an attempt to test whether the propensity of Asian
populations to manifest noneosinophilic polyps is due to genetic
factors, we evaluated the eosinophilic marker ECP and evidence
for eosinophilia in the pathology report of polyp and sinus tissue
collected during functional endoscopic surgery in a group of
second-generation Asian patients with CRS in Illinois and
compared them with those in patients of other ethnicities in
Illinois. We focused on study patients with both parents from
Asian countries who were born and raised in the United States.
Such patients come from the same genetic pool as their parents
but have presumably been exposed to environmental factors
present in the United States. Our findings demonstrated reduced
eosinophilia in Asian patients with CRSwNP who were born and
raised in the United States.
A consecutive series of 296 patients with CRSwNP who
underwent surgery at Northwestern University from 2005 to
2013 were included. Patients with self-reported Asian ancestry
and born in the United States were identified as second-generation
Asian. Twenty-three patients had identified themselves as Asian
(including Chinese, Korean, Japanese, and Malaysian), out of
which 11 were second generation and were included. The rest
were excluded from the study. Original pathology reports of polyp
and sinus tissue obtained during surgery were reviewed for
reported eosinophilia. The tissue would have been reported as
eosinophilic by the pathologists if eosinophils comprised more
than 10% of inflammatory cells in the studied area. Furthermore,
in 161 of the enrolled cases, tissue homogenates of polyp and/or
uncinate tissue (UT) were available in a prospectively collected
biorepository and were analyzed for ECP. UT was used as
representative of sinus and upper nasal tissue. Previous studies
have shown that NPs and UT of patients with CRSwNP from the
United States have a significantly higher number of eosinophils
than does control UT.2 ECP levels were measured by ELISA us-
ing the Mesacup ECP Test Kit from MBL (Woburn, Mass). The
ECP concentration was measured as ng/mL. The level was
adjusted to total protein concentration in each sample, which
was measured as mg/mL. All ECP levels were reported as
ng/mg of total protein. Physician diagnosis of asthma and atopy
was recorded as part of the study and was double-checked by
using chart review. Atopy was defined by evidence of allergic
sensitization to aeroallergens by using skin prick test or
Immunocap testing. The study was approved by the Northwestern
University institutional review board.
Comparisons among groups in terms of ECP levels were
assessed by using Kruskal-Wallis and Dunn’s multiple compar-
isons tests. Comparisons between groups in terms of eosinophilic
polyps, asthma, and atopy were done by using Fisher exact test.
Adjusting for age and sex for the above analyses was performed
by logistic regression. These statistical analyses were performed
using IBM SPSS, version 22. A P value of less than .05 was
considered statistically significant.
Levels of ECP in polyp (mean, 179.4 vs 1256 ng/mg; P < .001)
and UT samples (mean, 133.6 vs 838.6 ng/mg; P < .001) were
significantly lower in tissue from second-generation Asian versus
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Outcome definitions
The cohort-specific rhinitis and asthma definitions, aeroallergens tested,
and frequencies of follow-up are provided in Table E1. Parent-completed
questionnaires were used to collect data on rhinitis and asthma. Aeroallergen
sensitization was assessed as any specific IgE level of 0.35 kU/L or more for
BASME, GINI/LISA, and PIAMA. For CAPPS and SAGE, sensitization was
assessed by using skin prick testing. A positive reaction was defined as having
a wheal diameter of 3 mm or more. Although not all cohorts had information
on all aeroallergens, several aeroallergens were tested in each cohort
(Table E1). Each cohort received ethical approval from its local authorized
institutional review board. Statistical analyses were conducted in R, version
2.13.1 (www.r-project.org).
Genetic analyses
The 7 SNPs examined in this study were in Hardy-Weinberg equilibrium
(P > .01). For BAMSE, these SNPs were genotyped in a subset of the
cohort (N 5 2033 with DNA extracted from blood samples available) by
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
(SEQUENOM, Inc, San Diego, Calif). For the CAPPS, GINI/LISA, PIAMA,
and SAGE cohorts, information on these 7 SNPs was extracted from imputed
genome-wide data. All imputed allele dosage data were recoded to hard cod-
ing (0, 1, and 2) before further analysis. As a sensitivity analysis, the longitu-
dinal model results for the GINI/LISA cohort were compared using hard and
allele dosage coding for the SNPs and the results were very consistent.
For GINI/LISA, DNA samples from 1027 children and 69 children were
analyzed using the Affymetrix Human SNPArrays 5.0 and 6.0, respectively.
Genotypes were called using the BRLMM-P (Affymetrix 5.0) or BIRDSEED
V2 algorithm (Affymetrix 6.0). The genotype data were subjected to quality
control filters on the variant and individual levels. Variants were excluded on
the basis of the following criteria: a call rate below 95%, a minor
allele frequency below 1%, or a Hardy-Weinberg equilibrium P value below
13 1025 (;18% excluded). Only those individuals who had a call rate above
95%, a heterozygosity valuewithin64 SDs of themean, and who passed a sex
check and the similarity quality control step based on multidimensional
scaling plots were retained for subsequent imputation. The genotype data
were prephased using SHAPEIT v2E1,E2 and imputed using IMPUTE v2E3
against reference haplotypes from the 1000 Genomes Project (Phase I
integrated variant set [v3; includes individuals from all ancestries]; March
2012, updated August 26, 2012; limited to variants with more than 1 minor
allele copy). All 7 SNPs used for the present analysis were imputed with
good imputation quality (IMPUTE v2 INFO > 0.94).
For PIAMA,DNAwas extracted from blood or buccal swabs. DNA of 1377
children was genotyped on the Illumina Omni Express Exome Chip and DNA
of 288 children was genotyped with the Omni Express chip, both at the
Genomics Facility of the University Medical Center Groningen. DNA of 404
children was genotyped at the Centre National de Genotypage (CNG, Evry,
France) as part of the GABRIEL consortium.E4 SNPs were harmonized by
base-pair position annotated to genome build 37, name, and annotation of
strand for each platform. Discordant or duplicate SNPs or SNPs that showed
large differences in allele frequencies (>15 %) were removed. After qualitycontrol, a total of 1968 individuals remained and imputation was performed
per platform using IMPUTE 2.0 against the reference data set of the CEU
panel of the 1000 Genomes project (version March 2012). SNPs of high
quality (info-score IMPUTE >_ 0.7) were merged into 1 data set using GTOOL
and used for further analysis.
For CAPPS and SAGE, data on only 4 SNPs (rs2305480, rs7216389,
rs12603332, and rs3744246) were available. In total, 956 samples from
parents and children were genotyped using the Illumina HumanHap550 SNP
Array. Genotypes were subjected to the following quality control filters for
variants and individual samples. Variants were excluded on the basis of the
following criteria: a call rate below 95%, a minor allele frequency below 1%,
failure of Hardy-Weinberg equilibrium P value below 1 3 1024, and SNPs
with more than 2 Mendelian errors. Individual samples were retained if they
had a call rate of more than 97% and a heterozygosity value within 63 SDs
of the mean, and samples additionally had to pass gender and Mendelian
transmission error checks. Multidimensional scaling was used to check for
population stratification and to identify monozygotic twins (n 5 2) and
duplicate samples. Imputation was performed using MaCHE5 and HapMap2
r22 reference population. SNPs needed to be imputed with an r2 >_ 0.99 to
be used in the analysis.
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TABLE E1. Characteristics of participating cohorts
Cohort (country) Full name of cohort Study type Recruitment
Sample
size*
Ages (y)
availabley Rhinitis definition Asthma definition Aeroallergens tested
BAMSE (Sweden) Children, Allergy,
Milieu, Stockholm,
Epidemiological
SurveyE6
Population-based birth
cohort with wheeze
nested case-control
1994-1996 1953 4, 8, 16 Symptoms (sneezing,
runny or blocked nose,
itchy, red, and watery
eyes) after exposure to
furred pets or pollen or
a medical diagnosis of
allergic rhinitis since
previous questionnaire
At least 4 episodes of
wheeze in the last 12
mo or at least 1 episode
of wheeze with
occasional or regular
use of prescribed
inhaled corticosteroids
in the last 12 mo
Birch, cat, dog, house dust mite
(Dermatophagoide s pteronyssinus),
mold (Cladosporium herbarum),
mugwort, timothy grass
CAPPS (Canada) Canadian Asthma
Primary Prevention
StudyE7
Randomized controlled
study with asthma
intervention
1995 80 7 Medical diagnosis of
allergic rhinitis
assessed at 7-y
follow-up
Medical diagnosis of
asthma assessed at
7-y follow-up
Alternaria, cat, cockroaches, dog,
feathers, grass, house dust mites,
mold (C herbarum), ragweed,
trees, weeds
GINIplus
(Germany)
German Infant study
on the influence
of Nutritional
Intervention plus
environmental and
genetic influences on
allergy developmentE8
Population-based birth
cohort. Subset for
nutritional intervention
1995-1998 612 6, 10 Medical diagnosis of
allergic rhinitis or hay
fever during the last
12 mo
Medical diagnosis of
asthma during the
last 12 mo
Birch, cat, dog, house dust mite (D
pteronyssinus), mold (Cladosporium
herbarum), mugwort, rye, timothy
grass
LISAplus
(Germany)
Lifestyle-related factors,
Immune System and
the development of
Allergies in East and
West Germany plus the
influence of traffic
emissions and genetics
studyE9
Population-based birth
cohort
1997-1999 484 6, 10 Medical diagnosis of
allergic rhinitis or hay
fever during the last
12 mo
Medical diagnosis of
asthma during the
last 12 mo
Birch, cat, dog, house dust mite (D
pteronyssinus), mold (C herbarum),
mugwort, rye, timothy grass
PIAMA (The
Netherlands)
Prevention and Incidence
of Asthma and Mite
AllergyE10
Population-based birth
cohort. Subset for
mattress cover
intervention
1996-1997 1386 4, 8, 11/12 Sneezing, runny/blocked
nose during the last 12
mo without cold or flu
Medical diagnosis of
asthma during the
last 12 mo
Alternaria,§ birch, cat, Dactylis, dog,§
house dust mite (D pteronyssinus)
SAGE (Canada) Study of Asthma
Genes and the
EnvironmentE11
Population-based cohort
with asthma nested
case-control
1995 109 8 Medical diagnosis of
allergic rhinitis
assessed at 8-y
follow-up
Medical diagnosis of
asthma assessed at
8-y follow-up
Cat, dog, feathers, grass, ragweed,
trees, weeds
*Number of children with health outcome information for at least 1 time point and genotype data.
Ages at which both rhinitis and aeroallergen sensitization data were available, and therefore allergic rhinitis could be defined.
Data from only the Munich center from these 2 combined German cohorts were included in the current analysis, referred to as GINI/LISA throughout the article, because genome-wide genetic data were available only for that study area
(Wesel, Leipzig, and Bad Honnef were excluded).
§Available only at ages 4 and 8 y.
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TABLE E2. Pooled and cohort-specific numbers of cases and
controls (cases/controls)
Age (y) Pooled BAMSE CAPPS GINI/LISA PIAMA SAGE
Allergic rhinitis*
4 152/1675 102/1319 - - 50/356 -
6 80/791 - - 80/791 - -
7 22/58 - 22/58 - -
8 437/2398 253/1426 - - 159/888 25/84
10 125/593 - - 125/593 - -
11/12 154/505 - - - 154/505 -
16 411/828 411/828 - - - -
Allergic rhinitis with concomitant asthma
4 37/1594 28/1246 - - 9/348 -
6 12/780 - - 12/780 - -
7 9/53 - 9/53 - - -
8 115/2313 63/1367 - - 37/876 15/70
10 25/585 - - 25/585 - -
11/12 25/502 - - - 25/502 -
16 69/797 69/797 - - - -
Allergic rhinitis without concomitant asthma
4 114/1594 73/1246 - - 41/348 -
6 68/780 - - 68/780 - -
7 13/53 - 13/53 - - -
8 318/2313 186/1367 - - 122/876 10/70
10 98/585 - - 98/585 - -
11/12 129/502 - - - 129/502 -
16 333/797 333/797 - - - -
*Age-specific controls were defined as those without allergic rhinitis.
Age-specific controls were defined as those without allergic rhinitis or asthma.
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TABLE E3. Genetic information for the 7 SNPs at the 17q21 locus
SNP Gene
Noneffect
allele/effect allele Position (build 37)
BAMSE* CAPPSy GINI/LISAy PIAMAy SAGEy
N EAF N EAF N EAF N EAF N EAF
rs2305480 GSDMB G/A 38062196 1934 0.47 80 0.47 1096 0.45 1386 0.44 109 0.40
rs7216389 GSDMB C/T 38069949 1933 0.48 80 0.48 1096 0.49 1386 0.51 109 0.54
rs4065275 ORMDL3 A/G 38080865 1939 0.50 - - 1096 0.50 1386 0.52 - -
rs8076131 ORMDL3 A/G 38080912 1935 0.47 - - 1096 0.45 1386 0.44 - -
rs12603332 ORMDL3 T/C 38082807 1948 0.49 79 0.50 1096 0.50 1386 0.52 109 0.56
rs17608925 ORMDL3 T/C 38082831 1932 0.10 - - 1096 0.11 1386 0.11 - -
rs3744246 ORMDL3 C/T 38084350 1936 0.19 80 0.19 1096 0.21 1386 0.20 109 0.20
The SNPs are in linkage disequilibrium (r2 > 0.2, D9 > 0.9).
EAF, Effect allele frequency; GSDMB, gasdermin B; N, number of children with health outcome information for at least 1 time point and genotype data; ORMDL3, ORM1-like
protein 3.
*Genotypes derived from genotyped data.
Genotypes derived from imputed data.
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TABLE E4. Cohort-specific associations between 7 SNPs at the 17q21 locus and allergic rhinitis*
SNP (effect allele)
BAMSE (up to 16 y) CAPPS (at 7 y) GINI/LISA (up to 10 y) PIAMA (up to 12 y) SAGE (at 8 y)
N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI)
rs2305480 (A) 1934 0.87 (0.75-1.00) 80 1.05 (0.52-2.13) 1096 0.80 (0.64-1.01) 1386 0.87 (0.72-1.06) 109 0.71 (0.36-1.40)
rs7216389 (T) 1933 1.15 (1.00-1.33) 80 0.98 (0.46-2.05) 1096 1.16 (0.93-1.44) 1386 1.14 (0.94-1.38) 109 1.25 (0.64-2.42)
rs4065275 (G) 1939 1.15 (1.00-1.33) - - 1096 1.09 (0.87-1.36) 1386 1.13 (0.93-1.38) - -
rs8076131 (G) 1935 0.87 (0.76-1.01) - - 1096 0.81 (0.65-1.02) 1386 0.87 (0.71-1.06) - -
rs12603332 (C) 1948 1.18 (1.03-1.36) 79 1.00 (0.47-2.12) 1096 1.09 (0.87-1.35) 1386 1.13 (0.93-1.37) 109 1.15 (0.60-2.22)
rs17608925 (C) 1932 0.97 (0.77-1.22) - - 1096 0.79 (0.52-1.20) 1386 0.83 (0.60-1.15) - -
rs3744246 (T) 1936 0.91 (0.76-1.08) 80 1.16 (0.49-2.76) 1096 0.88 (0.65-1.18) 1386 0.78 (0.61-1.00) 109 0.54 (0.21-1.40)
N, Number of children included in the model; OR, odds ratio.
*Models were adjusted for age except for CAPPS and SAGE for which only 1 time point was available. The SNPs are in linkage disequilibrium (r2 > 0.2, D9 > 0.9).
P < .05.
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